Mosquito saliva peptide vaccine has hVIVO upbeat
(Sharecast News) - Clinical development services business hVIVO confirmed on Wednesday that the National Institutes of Health had presented partial preliminary results from the recently-completed Phase I study of AGS-v at the American Society of Tropical Medicine and Hygiene's 67th annual conference in New Orleans.
Read more